Annual Report 2014 Annual Report 2014
Menu

Merck Group

Merck Group → highlights of 2014

Fit for2018

March26→
Merckannouncessharesplit

Subsequent to a doubling in the value of Merck shares since the beginning of 2011, Merck announces a share split in a ratio of 1: 2. The share split became effective on June 30.

May2→
Acquisitionofazelectronicmaterials

Through the acquisition of AZ for around € 1.9 billion, Merck expands its existing, highly profitable Liquid Crystals business with high-tech electronic materials. AZ materials are widely used in integrated circuits, flat-panel displays and light-emitting diodes, making AZ an important partner to the leading global electronic manufacturers.

August1→
NewCFOtakesoffice

Marcus Kuhnert joins Merck as Member of the Executive Board and Chief Financial Officer.

August27→
Merckbreaksgroundatanewpharmaceuticalmanufacturingsiteinchina

Merck holds the groundbreaking ceremony for its new pharmaceutical manufacturing site in Nantong, China. The new facility will be Merck’s second-largest worldwide. As of 2017, it will mainly focus on the bulk production and packaging of medicines referenced in China’s essential drug list.

September1→
Groundbreakingceremonyfornewglobalheadquarters

The expansion of the Merck site in Darmstadt into a contemporary global headquarters is clearly taking shape. The symbolic groundbreaking officially marks the launch of the “ONE Global Headquarters” project.

September18→
Merckannouncesplanstostrengthentheexecutiveboard

Effective January 1, 2015, Stefan Oschmann becomes Vice Chairman of the Executive Board. On the same date, Belén Garijo becomes a Member of the Executive Board and assumes the leadership of the Healthcare business sector.

September22→
MerckentersintoanagreementtoacquireSigma-Aldrich

Merck announces an agreement to acquire Sigma-Aldrich for US$ 17.0 billion. The combination would establish one of the leading players in the US$ 130 billion global life science industry. On December 5, Sigma-Aldrich shareholders approve the merger with Merck.

September30→
Mercklaunches“proudtobeanoriginal”employeecampaign

Merck kicks off a global communications campaign called “Proud to be an Original”. The campaign offers Merck’s 39,000 employees worldwide the opportunity to express their pride in working for Merck.

17.November→
MerckentersintostrategicalliancewithPfizerinimmuno-oncology

Merck and Pfizer will jointly develop and commercialize a highly promising anti-PD-L1 antibody from the Merck research pipeline. In value terms, the transaction is the largest so far in the biopharmaceutical industry for a single asset at this stage of development. Immuno-oncology is about mobilizing the body’s own immune system to fight tumor cells.

Nach oben